A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Korábbi kezelés

• Previous or planned bariatric surgery or fitting of a weight loss device.
• History of major depressive disorder within the 2 years prior to screening or depression.
• Treatment with a GLP1 containing preparation, either as part of treatment or while participating in another clinical study within the 3 months or 5 half-lives of the drug prior to screening.

Más betegség

• History of any clinically important disease or disorder, which, in the opinion of the Investigator, may put the participant at risk.
• History or presence of GI, renal, hepatic disease.
• Obesity induced by endocrine disorders such as Cushing's syndrome, insulinoma or Prader-Willi syndrome.
• Significant gastric and hepatobiliary disease.
• History of psychosis or bipolar disorder.

Laborértékek

• History of T1DM or T2DM or symptoms indicative of insulinopenia or poor glucose control.
• HbA1c ≥ 6.5% (48 mmol/mol), fasting serum glucose ≥ 126 mg/dL (7.0 mmol/L) or random glucose ≥ 200 mg/dL (11.1 mmol/L).
• History of acute or chronic pancreatitis or pancreatic amylase or lipase > 2 × ULN at screening.

Egyéb

• Vulnerable populations

• Participant must be 18 to 75 years of age inclusive.
• BMI: ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight related comorbidity.
• A stable, self-reported body weight for 3 months prior to screening.
• Male and female participants: Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
• Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
• Capable of giving signed informed consent.